DCDC2 Gene Deafness Autosomal Recessive Type 66 Genetic Test
Introduction
The DCDC2 gene is associated with a form of deafness known as autosomal recessive type 66 (DFNB66). This genetic test aims to identify mutations in the DCDC2 gene that may be causing the deafness. By undergoing this NGS genetic test, individuals can receive a definitive diagnosis and better understand the genetic cause of their hearing loss.
Test Details
- Test Name: DCDC2 Gene Deafness Autosomal Recessive Type 66 Genetic Test
- Components: NGS Technology
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Test Type: Ear Nose Throat Disorders
- Doctor: ENT Doctor
- Test Department: Genetics
Pre Test Information
Before undergoing the DCDC2 Gene Deafness Autosomal Recessive Type 66 Genetic Test, it is important to provide the following information:
- Clinical History of Patient who is going for IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test
- A Genetic Counselling session to draw a pedigree chart of family members affected with IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS11
Benefits of the Test
By undergoing the DCDC2 Gene Deafness Autosomal Recessive Type 66 Genetic Test, individuals can:
- Receive a definitive diagnosis for their hearing loss
- Better understand the genetic cause of their condition
- Manage the condition more effectively
- Make informed decisions about treatment options
- Receive genetic counseling and family planning guidance
- Gain insights into the likelihood of passing the condition on to future generations
Conclusion
The DCDC2 Gene Deafness Autosomal Recessive Type 66 Genetic Test offered by DNA Labs UAE is a valuable tool for diagnosing and understanding the genetic cause of deafness associated with the DCDC2 gene. By undergoing this test, individuals can receive a definitive diagnosis, manage their condition effectively, and make informed decisions about treatment options and family planning.
| Test Name | DCDC2 Gene Deafness autosomal recessive type 66 Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Ear Nose Throat Disorders |
| Doctor | ENT Doctor |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS11 |
| Test Details |
The DCDC2 gene is associated with a form of deafness known as autosomal recessive type 66 (DFNB66). This means that individuals with two copies of a mutated DCDC2 gene will have the condition, while those with only one copy are carriers and typically do not experience hearing loss. NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that uses advanced sequencing technology to analyze multiple genes simultaneously. In the case of DFNB66, NGS testing can identify mutations in the DCDC2 gene that may be causing the deafness. By undergoing an NGS genetic test for DFNB66, individuals can receive a definitive diagnosis and better understand the genetic cause of their hearing loss. This information can be useful for managing the condition and making informed decisions about treatment options. It can also help with genetic counseling and family planning, as it provides information about the likelihood of passing the condition on to future generations. |
